Pakistan’s pharmaceutical sector is gaining global recognition, thanks in part to the support of the Special Investment Facilitation Council (SIFC).

A world leader in consumer health, Haleon, has announced a $12 million investment in Pakistan aimed at expanding its production capacity, particularly for Panadol, to meet the growing demand in the country.

During the current financial year, Pakistan’s pharmaceutical exports have risen to $457 million, bolstered by the SIFC’s initiatives.

Data indicates that exports of therapeutic products including pharmaceuticals, surgical supplies, dietary supplements, and medical devices have reached a record $909 million.

According to sources in the Pakistan Pharma Manufacturers Association (PPMA), pharmaceutical exports surged by 34% in the fiscal year, attributed to the government’s reasonable pricing policy.

This deregulation aligns with international standards, fostering increased investment and production.

Major buyers of Pakistani medicines include Afghanistan, the Philippines, Sri Lanka, Uzbekistan, and Iraq, while countries like Kenya, Vietnam, Myanmar, and Thailand present significant export potential.

The sources predict that Pakistani pharmaceutical exports could reach $1.5 billion in the global market by 2030.